Take Delhi-based Tulips, a producer of cotton products and swipes, which took a quick call to reposition itself from being a largely cosmetic product to becoming a medical consumable. It didn’t require much investment, just smart thinking, says the company. “We felt there was a huge dearth of coronavirus testing swabs in India, and they were being imported at the time the virus hit us,” says Rahul Jain, a partner in the medium enterprise whose business spans 15 countries. The firm had the requisite infrastructure, which had been put in place over the last two decades, the technical expertise, and the necessary R&D. It was also making many machinery parts in-house. “In sum, our in-house research and development team had to repurpose the existing infrastructure as per the WHO standards,” adds Jain.